HPTN 027

Status:Completed
Phase:I
Principal Investigator(s):Laura Guay, MD, Francis Mmiro, MBChB, FRCOG
Objective:The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, ALVAC-HIV vCP1521, given to infants born to HIV-1 infected mothers in Uganda.   Results: HIV-1 exposed infants are capable of generating low levels of cellular immune responses to ALVAC vaccine, similar to responses seen in adults.
Prevention Option(s):HIV Vaccine
Study Design:Double-blind, Randomized
Arms and Assigned Interventions
DescriptionOne 1-ml dose of HIV-1 vaccine administered after birth on or before Day 3 and at weeks 4, 8, and 12.
Mode of Delivery
ARMsExperimental
Results: Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1 Infected Women in Uganda
Official Code: NCT00098163
Related Publications:
Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa
Immunoprophylaxis to prevent mother-to-child transmission of HIV-1
Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors
Safety profile of recombinant canarypox HIV vaccines
Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda
Trial Sponsors: NIAID, NICHD, NIDA, NIMH
Start Date
End Date
none
May 1, 2009
Enrollment:60
Age range: 18 Years ↔ any
Population: